Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$6.70 USD
-0.02 (-0.30%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $6.70 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Adverum Biotechnologies (ADVM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$33.57 | $60.00 | $15.00 | 401.04% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Adverum Biotechnologies comes to $33.57. The forecasts range from a low of $15.00 to a high of $60.00. The average price target represents an increase of 401.04% from the last closing price of $6.70.
Analyst Price Targets (7 )
Broker Rating
Adverum Biotechnologies currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, seven are Strong Buy, representing 87.5% of all recommendations. A month ago, Strong Buy represented 87.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.25 | 1.25 | 1.29 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/18/2024 | Chardan Capital Markets | Daniil Gataulin | Strong Buy | Strong Buy |
7/14/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
7/9/2024 | Not Identified | Not Identified | Hold | Hold |
6/25/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
4/30/2024 | H.C. Wainwright & Co. | Matthew Caufield | Not Available | Strong Buy |
4/29/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
4/26/2024 | LadenburgThalmann | Aydin Huseynov | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.25 |
# of Recs in ABR | 8 |
Average Target Price | $33.57 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | -1.27 |